These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35068379)

  • 1. Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.
    Zhou Y; Xu X
    Hematology; 2022 Dec; 27(1):105-112. PubMed ID: 35068379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction of novel agents in the treatment of primary CNS lymphoma.
    Grommes C; Nayak L; Tun HW; Batchelor TT
    Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Jul; 65(7):882-894. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New treatment strategies for primary lymphoma of the central nervous system].
    Seidel S; Kaulen L; von Baumgarten L
    Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma].
    Wang Y; Wang X; Zhao Y; Tao R; Zhu Y; Zhao R; Xu J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):46-9. PubMed ID: 24602732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary central nervous system lymphoma: Novel precision therapies.
    Mondello P; Mian M; Bertoni F
    Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
    Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
    Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
    Chihara D; Dunleavy K
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
    Hu BN; Yang X; Yuan YP; Chen YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.
    Calimeri T; Steffanoni S; Foppoli M; Ponzoni M; Ferreri AJM
    Expert Opin Ther Targets; 2021 Sep; 25(9):749-760. PubMed ID: 34606736
    [No Abstract]   [Full Text] [Related]  

  • 20. Targets and treatments in primary CNS lymphoma.
    von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
    Leuk Lymphoma; 2024 Aug; 65(8):1055-1067. PubMed ID: 38659230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.